Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00573495 · ClinicalTrials.gov registry record · Phase 1
Multipeptide Vaccine for Advanced Breast Cancer
A Phase 1 study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT00573495: Completed Phase 1 study, sponsored by University of Pennsylvania.
NCT00573495 is a Phase 1 study that has completed, run by University of Pennsylvania. The registered enrollment target is 11 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00573495, a Phase 1 study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
This is a study on how to activate the immune system with a vaccine. The vaccine is made up of two proteins found in breast cancer: telomerase and survivin. The vaccine is given in combination with other drugs that may also have an effect on the immune system and attack the cancer. The goals of the study are: 1. to test the safety of the combination of agents 2. to find out what effects the treatment has on advanced breast cancer
Interventions
- BIOLOGICAL hTERT/Survivin Multi-Peptide Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2007-11 |
| Est. Completion | 2013-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00573495
The ClinicalTrials.gov registry entry for NCT00573495 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which hTERT/Survivin Multi-Peptide Vaccine is the first listed.
NCT00573495 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00573495 about?
NCT00573495 is a clinical study titled "Multipeptide Vaccine for Advanced Breast Cancer". This is a study on how to activate the immune system with a vaccine. The vaccine is made up of two proteins found in breast cancer: telomerase and survivin. The vaccine is given in combination with other drugs that may also have an effect on the immune system and attack the cancer. The goals of the...
What is the current status of trial NCT00573495?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2007-11. Estimated completion is 2013-02.
What interventions are being tested in trial NCT00573495?
The interventions under investigation include: hTERT/Survivin Multi-Peptide Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00573495?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.